N-13 Ammonia Cardiac PET Perfusion Imaging

Introduction

N-13 ammonia is a cyclotron-produced PET myocardial perfusion tracer whose short half-life, low positron energy, and high myocardial extraction make it one of the most quantitatively capable perfusion agents in nuclear cardiology — at the cost of needing an on-site cyclotron. Approved by the FDA in 2000 for evaluating myocardial perfusion at rest and under pharmacologic stress, it produces images of excellent quality and supports absolute measurement of myocardial blood flow (MBF) and coronary flow reserve. ^{1, 2}

Cardiac PET perfusion has three practical tracers, and the choice among them is largely a physics-and-logistics trade-off. Rubidium-82 is generator-produced and needs no cyclotron, but its very high positron energy blurs the image. F-18 flurpiridaz has near-ideal extraction and a half-life long enough for unit-dose distribution. N-13 ammonia sits between them: a 9.97-minute half-life that demands local production, but a low positron energy and high first-pass extraction that reward it with sharp images and reliable flow quantification. ^{2, 4} Understanding why comes down to the tracer's decay physics, its behavior in tissue, and the kinetic modeling that turns a dynamic scan into a blood-flow number.

This guide explains the physics and clinical use of N-13 ammonia cardiac PET, the on-site production logistics that shape a program, the kinetic modeling behind absolute blood-flow measurement, and the quality control a medical physicist should own. DRPS supports these programs through its PET/CT and nuclear medicine physics and accreditation support services across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

What N-13 ammonia is and how it behaves

N-13 ammonia is [13N]NH3, a small neutral molecule that crosses the myocyte cell membrane and is metabolically trapped in proportion to blood flow. After intravenous injection, it clears rapidly from the blood pool and is extracted by viable myocardium, where it is incorporated into glutamine via glutamine synthetase and retained long enough to image. ^{1, 2} The combination of rapid blood clearance and metabolic trapping is what produces the high myocardial-to-background contrast that ammonia is known for.

Nitrogen-13 is the longest-lived nitrogen radioisotope, with a physical half-life of 9.965 minutes, and it decays essentially 100 percent by positron emission. ³ That short half-life is the defining constraint of the whole program: the tracer cannot be shipped from a regional radiopharmacy, so it must be made on site by a cyclotron, typically via the 16O(p,α)13N reaction on water, and delivered within a few minutes. The upside of the short half-life is low patient radiation dose and the ability to repeat rest and stress acquisitions in a single session.

For the production side of this equation, see our companion article on cyclotron F-18 production; many of the same facility, licensing, and radiochemistry principles apply to N-13.

Where it fits among cardiac PET tracers

Cardiac PET perfusion is dominated by three agents, and ammonia's niche is quantitative accuracy with excellent image quality. Compared with generator-produced Rb-82, ammonia offers better spatial resolution and higher extraction; compared with F-18 flurpiridaz, it lacks the convenience of distribution but is well established and shares the same dynamic-imaging framework for flow. ^{2, 4} The trade-offs are best seen side by side, which the table in the next section makes explicit.

Key Technical Principles

Decay physics and why the half-life dominates the workflow

Radioactive decay is exponential, so the activity of an N-13 dose falls as:

$$A(t)=A_0{e}^{-\lambda t},\lambda =\frac{\ln 2}{T_{1/2}}=\frac{0.693}{9.965\text{min}}=0.0695{\text{min}}^{-1}$$

The consequence is stark. Ten minutes after calibration — barely longer than one half-life — only about half the activity remains:

$$\frac{A(10)}{A_0}=e^{-0.0695\times 10}=e^{-0.695}\approx 0.499$$

and after 30 minutes less than 12 percent remains. This is why the cyclotron, radiochemistry, and PET suite must be tightly coupled, and why rest-stress timing is unforgiving: every minute of delay between production and injection costs measurable counts.

Positron range and intrinsic resolution

PET resolution has a physical floor set by positron range — the distance a positron travels before it annihilates and produces the two 511 keV photons that are actually detected. Higher positron energy means a longer range and more blur. N-13 emits positrons with a maximum energy of about 1.19 MeV (mean near 0.49 MeV), substantially lower than Rb-82's roughly 3.4 MeV maximum, so ammonia's intrinsic resolution is markedly better. ^{2, 4} For resolving thin or hypertrophied myocardial walls and for accurate regional flow, that difference is clinically meaningful. Our article on PET spatial resolution and positron range develops this physics in general terms.

Extraction, flow, and the roll-off problem

The fraction of tracer extracted on first pass falls as flow rises — a saturable relationship described by the Renkin–Crone model:

$$E=1-e^{-PS/F}$$

where $PS$ is the permeability–surface-area product and $F$ is flow. The net uptake rate is then:

$$K_1=E\cdot F=F\left(1-e^{-PS/F}\right)$$

N-13 ammonia has a high permeability–surface-area product, giving a high first-pass extraction (roughly 80 percent) that stays relatively high even at stress flows, so the measured uptake tracks true flow better than lower-extraction tracers. ^{2, 4} The extraction correction embedded in the kinetic model compensates for the residual roll-off.

From dynamic scan to blood flow

Absolute MBF is recovered by acquiring the study dynamically from the moment of injection and fitting a tracer kinetic model to the arterial input and myocardial tissue curves. The workhorse is the one-tissue-compartment model:

$$\frac{d{C}_t(t)}{dt}=K_1{C}_a(t)-k_2{C}_t(t)$$

where $C_a$ is the arterial (blood-pool) activity, $C_t$ is the tissue activity, $K_1$ relates to flow through extraction, and $k_2$ is the washout rate. ² Coronary (myocardial) flow reserve is simply the ratio of stress to rest flow:

$$\text{CFR}=\frac{{\text{MBF}}_{\text{stress}}}{{\text{MBF}}_{\text{rest}}}$$

Because resting flow scales with cardiac workload, rest MBF is commonly normalized to the rate–pressure product (RPP = heart rate × systolic blood pressure):

$${\text{MBF}}_{\text{corr}}={\text{MBF}}_{\text{rest}}\times \frac{10000}{\text{RPP}}$$

Worked example: computing flow reserve

Suppose a dynamic ammonia study yields a resting MBF of 0.80 mL/min/g at a heart rate of 70 bpm and systolic pressure of 140 mmHg, and a stress MBF of 2.40 mL/min/g. The rest RPP is $70\times 140=9800$, so the workload-corrected rest flow is:

$${\text{MBF}}_{\text{corr}}=0.80\times \frac{10000}{9800}=0.816\text{mL/min/g}$$

and the coronary flow reserve is:

$$\text{CFR}=\frac{2.40}{0.816}=2.9$$

A global CFR below about 2.0 is generally regarded as abnormal and carries adverse prognostic weight, so a value near 2.9 is reassuring. ² The point for a physicist is that this number is only as good as the dynamic framing, the input-function definition, and the co-registration behind it.

Comparison of cardiac PET perfusion tracers

The table's message is that ammonia trades logistical convenience for physics: if a site already has a cyclotron, it delivers image quality and quantitative accuracy that generator tracers cannot match. ^{2, 4}

Clinical Impact

N-13 ammonia PET delivers high diagnostic accuracy for coronary artery disease and adds absolute blood-flow information that changes management. Relative perfusion imaging can miss balanced, multivessel disease because every territory is reduced together; absolute MBF and CFR unmask it by showing globally depressed flow. ² Ammonia's high extraction and low positron energy make those flow numbers more reliable and its images sharper, which matters most in the patients who are hardest to image.

The short half-life is a clinical asset as well as a constraint. Low tracer dosimetry — an effective dose on the order of 1 to 2 mSv for combined rest and stress from the tracer itself — keeps total study dose low, particularly relative to older SPECT protocols, and the rapid decay allows rest and stress imaging in one visit. ¹ For flow-limited or high-risk patients, quantitative CFR provides prognostic stratification that a relative scan alone cannot, and it supports decisions about revascularization and microvascular disease.

Ammonia also anchors the quantitative-imaging ecosystem in a PET cardiology program alongside Rb-82 cardiac PET and quantitative myocardial blood flow measurement. The physics that gives it clean images — short positron range, high extraction — is the same physics that makes it a benchmark against which newer tracers such as F-18 flurpiridaz are compared.

Practical Optimization Tips

A robust N-13 ammonia program depends on coupling production, acquisition, and analysis tightly.

1. Synchronize the cyclotron and the scanner

Because half the activity is gone in ten minutes, schedule production so the dose reaches the patient within a small, fixed window, and calibrate the dose to the injection time, not the production time. Build the rest-stress sequence around cyclotron availability and let decay-corrected activity, not nominal activity, drive the protocol.

2. Frame the dynamic acquisition correctly

MBF quantification requires list-mode or finely framed dynamic data capturing the first-pass blood-pool peak (short early frames, for example a few seconds each) followed by longer tissue frames. Verify the framing scheme before go-live; a coarse early frame set corrupts the input function and biases flow.

3. Guard PET-CT co-registration

Attenuation-correction misregistration between the low-dose CT and the emission data is the classic cause of artifactual anterior or lateral "defects." Check and, if needed, manually correct alignment on every stress study, and prefer a CT acquired to match the emission respiratory state.

4. Verify tracer quality on every batch

Each N-13 batch needs radiochemical purity, radionuclidic purity (half-life confirmation), and pH/appearance checks per the compounding standard, with an accurate dose calibrator setting for N-13. Document the batch record before release.

5. Standardize the pharmacologic stress and vitals capture

Record heart rate and blood pressure at rest and peak stress so rate-pressure-product correction is possible, and standardize the vasodilator protocol so CFR values are comparable across patients and over time.

Common pitfalls to avoid

• Calibrating dose to production time. With a 10-minute half-life, a few minutes' error is a large activity error.
• Using perfusion-only framing. Without early short frames, absolute MBF cannot be computed reliably.
• Skipping co-registration review. AC misalignment mimics ischemia and is the most common artifact.
• Neglecting RPP. Uncorrected rest flow inflates or deflates CFR depending on workload.
• Treating N-13 like a distributable tracer. The program lives or dies by on-site production logistics.

Regulatory Considerations

N-13 ammonia is byproduct material for medical use, so its program sits under NRC or Agreement State authority, FDA drug requirements, and PET compounding standards. Medical use of the tracer falls under 10 CFR Part 35, which governs authorized users, the radiation safety officer's responsibilities, dose measurement, and record-keeping; on-site production and compounding are additionally governed by FDA current good manufacturing practice for PET drugs and by USP compounding standards for radiopharmaceuticals. ⁵ The dose calibrator must be set and checked for N-13, and each batch documented for radiochemical and radionuclidic purity.

Program accuracy and safety also draw on professional guidance. SNMMI and ASNC cardiac PET documents describe acquisition, dynamic framing, and blood-flow quantification methodology, and ICRP dosimetry publications provide the dose coefficients used to estimate patient effective dose. ^{2, 6} Absolute quantification, in particular, is a methodology that benefits from standardization; the joint SNMMI/ASNC position paper on clinical MBF quantification is the reference framework for how flow should be measured and reported. ²

Jurisdiction depends on the material and the state. Radioactive material — including N-13 — is regulated by the NRC or an Agreement State, while the PET/CT scanner's x-ray (CT) component is regulated by the FDA and the state. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use of byproduct material under their own radiation-control programs, while Washington DC and Delaware are regulated directly by the NRC for radioactive material. A facility must confirm which authority issues its license and align its ammonia program — production, compounding, dosimetry, and QC — with those requirements. This is best coordinated with radioactive material license support, radiation safety officer consulting, and PET/CT physics support.

Frequently Asked Questions (FAQs)

What is N-13 ammonia used for?

N-13 ammonia is a positron-emitting radiopharmaceutical used for PET myocardial perfusion imaging at rest and under pharmacologic stress. It evaluates regional and global myocardial blood flow to assess known or suspected coronary artery disease, and it supports absolute quantification of myocardial blood flow and coronary flow reserve. It was approved by the FDA in 2000 for this indication.

Why does N-13 ammonia require an on-site cyclotron?

N-13 has a physical half-life of only about 9.97 minutes, so it decays too quickly to be distributed from a central radiopharmacy the way a longer-lived tracer can. Practical clinical use therefore requires an on-site or very nearby cyclotron and radiochemistry to produce and deliver each dose within a few half-lives, which is the main logistical barrier to wider adoption.

How does N-13 ammonia compare with Rb-82 for cardiac PET?

N-13 ammonia has a much longer half-life than Rb-82 (about 10 minutes versus about 76 seconds), a lower positron energy, and a shorter positron range, which generally yields sharper images and high first-pass myocardial extraction. Rb-82 is generator-produced and needs no cyclotron, making it more accessible, but its high positron energy degrades spatial resolution. Both are validated for absolute myocardial blood flow.

Can N-13 ammonia measure absolute myocardial blood flow?

Yes. Dynamic acquisition beginning at injection, combined with tracer kinetic modeling — typically a one- or two-tissue-compartment model — allows estimation of absolute myocardial blood flow in mL/min/g at rest and stress, and the ratio of stress to rest flow gives coronary (myocardial) flow reserve. High extraction makes ammonia well suited to this quantification.

What is the radiation dose from an N-13 ammonia PET study?

Because N-13 decays rapidly, the effective dose from the ammonia tracer alone is low — on the order of about 1 to 2 mSv for a combined rest and stress study — though the total patient dose also includes the CT used for attenuation correction and any calcium scoring. This favorable tracer dosimetry is one of the advantages of short-lived PET perfusion agents.

Why is the positron range important for cardiac PET image quality?

A positron travels a short distance before annihilating, and the resulting blur sets a physical floor on spatial resolution. N-13 emits positrons with a lower maximum energy (about 1.19 MeV) and shorter range than Rb-82, so its intrinsic resolution is better. This matters for resolving thin myocardial walls and for accurate regional blood-flow measurement.

What quality control is specific to N-13 ammonia cardiac PET?

Beyond routine PET/CT daily QC and NEMA performance testing, an ammonia program needs radiochemical and radionuclidic purity checks on each batch, accurate dose calibrator settings, tight rest-stress timing given the short half-life, verified list-mode/dynamic framing for kinetic modeling, and careful PET-CT co-registration to avoid attenuation-correction artifacts that mimic perfusion defects.

Key Takeaways

• The 9.97-minute half-life defines the program. N-13 must be produced on site and dosed to injection time, not production time. ³
• Physics rewards it with image quality. Low positron energy (about 1.19 MeV max) and short range give sharper images than Rb-82. ^{2, 4}
• High extraction supports accurate flow. First-pass extraction near 80 percent lets measured uptake track true flow with modest roll-off correction. ^{2, 4}
• Absolute MBF and CFR add clinical value. Dynamic acquisition plus compartmental modeling unmasks balanced multivessel disease and adds prognosis. ²
• Low tracer dose is a real advantage. Combined rest-stress tracer dose is on the order of 1 to 2 mSv, excluding CT. ¹
• QC is program-specific. Batch purity, dynamic framing, RPP capture, and co-registration are the ammonia-specific failure points.

Conclusion

N-13 ammonia occupies a distinctive place in nuclear cardiology: a tracer whose short half-life makes it logistically demanding but whose decay physics — low positron energy, short range — and high myocardial extraction make it one of the best perfusion agents for image quality and quantitative blood flow. For a facility with a cyclotron, it delivers accuracy that generator tracers cannot, low patient dose, and validated absolute MBF and coronary flow reserve.

The medical physicist's role is to make that physics pay off in practice: coupling production to the scanner, framing the dynamic acquisition for reliable kinetic modeling, guarding co-registration, and verifying tracer quality on every batch. Programs that treat ammonia as a quantitative measurement — not just a perfusion picture — extract its full clinical value.

How DRPS Can Help

Diagnostic Radiation Physics Services supports cardiac PET programs from acceptance through routine operation. For N-13 ammonia, this may include PET/CT acceptance and NEMA performance testing, dynamic-framing and kinetic-modeling protocol validation, dose calibrator setup for N-13, attenuation-correction and co-registration review, batch QC and license support for on-site production, and integration with PET/CT and nuclear medicine physics, accreditation support, and radioactive material license support.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

Great perfusion imaging starts with great physics — and with N-13 ammonia, the physics is the whole point.

Related Resources

• Rubidium-82 cardiac PET MPI
• F-18 flurpiridaz cardiac PET MPI
• Quantitative myocardial blood flow with cardiac PET
• Cyclotron F-18 production
• PET spatial resolution and positron range
• PET/CT and nuclear medicine physics
• Accreditation support

References

1. U.S. Food and Drug Administration. Ammonia N 13 Injection — prescribing information. accessdata.fda.gov
2. Murthy VL, Bateman TM, Beanlands RS, Berman DS, Borges-Neto S, Chareonthaitawee P, et al. Clinical quantification of myocardial blood flow using PET: joint position paper of the SNMMI Cardiovascular Council and the ASNC. J Nucl Med. 2018;59(2):273-293. doi:10.2967/jnumed.117.201368. doi.org
3. National Nuclear Data Center, Brookhaven National Laboratory. Nuclear data for N-13 (half-life 9.965 min; 100% β+ decay). nndc.bnl.gov
4. deKemp RA, Renaud JM, Klein R, Beanlands RS. Radionuclide tracers for myocardial perfusion imaging and blood flow quantification. Cardiol Clin. 2016;34(1):37-46. doi:10.1016/j.ccl.2015.08.001. doi.org
5. U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
6. Juneau D, Erthal F, Ohira H, Mc Ardle B, Hessian R, deKemp RA, Beanlands RS. Clinical PET myocardial perfusion imaging and flow quantification. Cardiol Clin. 2016;34(1):69-85. doi:10.1016/j.ccl.2015.07.013. doi.org
7. Juneau D, Wu KY, Kaps N, Yao J, Renaud JM, Beanlands RSB, et al. Internal validation of myocardial flow reserve PET imaging using stress/rest myocardial activity ratios with Rb-82 and N-13-ammonia. J Nucl Cardiol. 2021;28(3):835-850. doi:10.1007/s12350-020-02464-y. doi.org
8. Murthy VL, Bateman TM, Beanlands RS, Berman DS, Borges-Neto S, Chareonthaitawee P, et al. Clinical quantification of myocardial blood flow using PET: joint position paper of the SNMMI Cardiovascular Council and the ASNC. J Nucl Cardiol. 2018;25(1):269-297. doi:10.1007/s12350-017-1110-x. doi.org
9. International Commission on Radiological Protection. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals. Ann ICRP. 2015;44(2S). icrp.org
10. U.S. Pharmacopeia. USP General Chapter <825> Radiopharmaceuticals — Preparation, Compounding, Dispensing, and Repackaging. usp.org